Clinical trials: Pancreatic Cancer Stage I
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
This phase I trial studies the side effects and best dose of CPI-613 when given together with combination chemotherapy in treating patients with metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01835041
- Testing
- 6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Neoplasms, Prostatic Neoplasms, Castration-Resistant
HTL0039732 in Participants With Advanced Solid Tumours
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with…
- Conditions
- Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms
- Trial name
- NCT05944237
- Testing
- HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cancer Research UK
Pancreatic Cancer, Adenocarcinoma
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
The purpose of this phase I study to determine the optimal dose for the combination of IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) chemotherapy in patients with pancreatic cancer.
- Conditions
- Pancreatic Cancer, Adenocarcinoma, Pancreatic Neoplasms
- Trial name
- NCT01383538
- Testing
- FOLFIRINOX, IPI-926
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Andrew Ko
Pancreatic Cancer
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
RATIONALE: Monoclonal antibodies, such as ganitumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01298401
- Testing
- ganitumab, capecitabine, gemcitabine hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 8 people
- Sponsor
- Radiation Therapy Oncology Group
Locally Advanced or Metastatic Pancreatic Cancer
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With…
- Trial name
- NCT03579836
- Testing
- BEY1107, Gemcitabine
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- BeyondBio Inc.
Anal Cancer, Carcinoma of the Appendix
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00654160
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Metastatic Pancreatic Ductal Adenocarcinoma
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
The investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT06904378
- Testing
- ONT01, Gemcitabine, Nab paclitaxel
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Lung Cancer
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.
- Conditions
- Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer
- Trial name
- NCT01012362
- Testing
- Pazopanib, Ixabepilone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Unresectable Pancreatic Cancer, Advanced Pancreatic Cancer
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study.
- Conditions
- Unresectable Pancreatic Cancer, Advanced Pancreatic Cancer, Lymph Node Metastases
- Trial name
- NCT06278454
- Testing
- NRT6008 Injection + Systematic chemotherapy
- Where
- 6 sites in China
- Volunteers
- 58 people
- Sponsor
- Chengdu New Radiomedicine Technology Co. LTD.
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian, Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid…
- Conditions
- Ovarian, Melanoma, Renal, Prostate
- Trial name
- NCT00423254
- Testing
- PSMA/PRAME
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mannkind Corporation
Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
This phase I trial is studying the side effects and best dose of dovitinib lactate when given together with gemcitabine hydrochloride and capecitabine in treating patients with advanced or metastatic solid tumors or advanced…
- Conditions
- Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT01497392
- Testing
- dovitinib lactate, gemcitabine hydrochloride, capecitabine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody.
- Conditions
- Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
- Trial name
- NCT06380816
- Testing
- UCB4594
- Where
- 4 sites in United Kingdom
- Volunteers
- 167 people
- Sponsor
- Cancer Research UK
Solid Tumors, Multiple Myeloma
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Conditions
- Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors
- Trial name
- NCT02110563
- Testing
- DCR-MYC
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Ovarian Cancer, Pancreatic Cancer
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
This is a Phase I, multi-center, open-label, dose-escalation study of DMUC5754A administered as a single agent by intravenous (IV) infusion to patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
- Trial name
- NCT01335958
- Testing
- DMUC5754A
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Genentech, Inc.
Neuroendocrine Tumor, Carcinoid Tumor
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT00804336
- Testing
- SOM230, RAD001
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Cancer, Ovarian Cancer
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
To find the recommended dose of TROP2- CAR-NK given intraperitoneally (directly into the abdominal cavity) to patients with highgrade serous ovarian cancer that has not responded to previous treatment or is resistant to treatment.
- Conditions
- Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma
- Trial name
- NCT05922930
- Testing
- TROP2-CAR-NK, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Pancreatic Cancer, Cancer
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
- Trial name
- NCT03403049
- Testing
- Carbon Ion, Gemcitabine + Cisplatin, Gemcitabine + Capecitabine
- Where
- 2 sites in United States, China
- Volunteers
- 14 people
- Sponsor
- Montefiore Medical Center